Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue

Stephen D. Mikolajczyk, Lisa S. Millar, Kathy M. Marker, Harry G. Rittenhouse, Robert L. Wolfert, Leonard S. Marks, M. Cristine Charlesworth, Donald J. Tindall

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

Human kallikrein (hK) 2 is an arginine-selective serine protease expressed predominantly in the prostate that has an 80% sequence identity with prostate-specific antigen. Expression of hK2 is elevated in the tumor epithelium compared to benign prostate tissue. We have purified, sequenced, and identified a novel hK2 complex in prostate tissue consisting of hK2 and a serine protease inhibitor known as protease inhibitor-6 (PI-6). This 64-kDa SDS-PAGE stable complex is elevated in the tumor and is approximately 10% of total hK2. No comparable complex of prostate-specific antigen was detected. PI-6, also known as cytoplasmic antiprotease, has been characterized as an intracellular inhibitor of trypsin and chymotrypsin-like proteases, which has high homology to plasminogen activator inhibitor 1 and 2. The physiological role of PI-6 in the prostate and its relationship to hK2 and prostate cancer are under investigation.

Original languageEnglish (US)
Pages (from-to)3927-3930
Number of pages4
JournalCancer research
Volume59
Issue number16
StatePublished - Aug 15 1999

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Identification of a novel complex between human kallikrein 2 and protease inhibitor-6 in prostate cancer tissue'. Together they form a unique fingerprint.

Cite this